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Introduction
Muckle-Wells syndrome (MWS), a phenotype within the
spectrum of cryopyrine-associated periodic syndrome
(CAPS) is characterized by excessive IL-1 release resulting
in chronic systemic and organ-specific inflammation
including sensorineural hearing loss. During continuous
anti-IL-1-therapy clinical symptoms are controlled and
hearing loss remains stable. Limited data exists about dis-
continuation of IL-1-inhibition during the course of
disease.
Objective
To report the case of a MWS patient, with sudden dete-
rioration of hearing loss due to discontinuation of anti-IL-
1-therapy and improvement of hearing after re-therapy.
Case report
A 29 year old female patient was diagnosed with MWS
at age 17. Her left ear had been deaf since early child-
hood. The patient experienced arthralgia, exanthema,
fatigue and progressive hearing loss of the right ear dur-
ing childhood. Anti-IL-1-therapy with Anakinra was
started 4 years after diagnosis. In 2007, she was switched
to Canakinumab resulting in complete resolution of
exanthema and arthralgia and improved fatigue. Hearing
loss was stable during therapy as documented by fre-
quent high frequency pure tone assessments (HFPTA).
When she became pregnant, MWS treatment was
changed from Canakinumab to Anakinra as suggested
by the safety profile. The patient gave birth to a healthy
boy, who has a CAPS mutation.
The patient decided to discontinue IL-1-inhibition
while breast-feeding. After four months off anti-IL-1-
therapy, her hearing had markedly deteriorated: HFPTA
demonstrated a decrease of 20-30 dB in frequencies
most relevant for speech discrimination, a substantially
impairment for a unilateral deaf patient. The patient
decided to stop breast-feeding and Canakinumab ther-
apy was immediately re-initiated. Two months later
improved hearing was documented with 5-10 dB but
still 10-25 dB less than before discontinuation.
Conclusion
Long-term IL-1-inhibition prevents decline of hearing
ability in CAPS. Withdrawal of treatment may result in
rapid and marked hearing loss. An early restart of anti-
IL-1-therapy may partially reverse hearing loss. This
indicates a window of opportunity for reversal of hear-
ing loss by IL-1-inhibition. To our knowledge, this is
the first case in which such a close connection between
IL-1-inhibition and hearing ability in MWS has been
documented. This case report shows the importance of
continuation of anti-IL-1-therapy during pregnancy and
breast-feeding to reduce the risk of sequel.
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